What do systematic reviews say?

21 questions · 21 findings · 7 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 4.8%GRADE not reported 16 · 76.2%Very low 2 · 9.5%Low 1 · 4.8%Moderate 1 · 4.8%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Group A: amino acids vs placebo · Behaviour: clinically important change in behaviour
  Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported
Direct match · question page
- Group A: omega‐3 fatty acids vs placebo · Behaviour: clinically important change in behaviour
  Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported
Direct match · question page
- Group B antipsychotic drugs: amisulpiride + needs‐focused intervention vs needs‐focused intervention · Behaviour: clinically important change in behaviour
  Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported
Direct match · question page
- Group B antipsychotic drugs: olanzapine + supportive intervention vs placebo + supportive intervention · Behaviour: clinically important change in behaviour
  Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported
Direct match · question page
- Group B cognitive behavioural therapy: cognitive behavioural therapy + supportive therapy vs supportive therapy · Behaviour: clinically important change in behaviour
  Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Omega‐3 vs placebo

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group B antipsychotic drugs: amisulpiride + needs‐focused intervention vs needs‐focused intervention

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group B antipsychotic drugs: olanzapine + supportive intervention vs placebo or supportive treatment

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group B cognitive behavioural therapy: cognitive behavioural therapy + supportive therapy vs supportive therapy

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group B cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo and cognitive and behavioural therapies

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group A: amino acids vs placebo

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group B cognitive behavioural therapy: cognitive behavioural therapy (specific preventive intervention) + needs‐based intervention + risperidone vs needs‐based intervention

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group C cognitive behavioural therapy: cognitive behavioural therapy + placebo vs placebo or supportive treatment

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group C cognitive behavioural therapy: cognitive behavioural therapy + supportive intervention vs non‐directive reflective listening + supportive intervention

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group C cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo or supportive treatment

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Cognitive training vs active control

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group C other: family treatment vs enhanced care

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group C other: integrated treatment vs usual care

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Intervention not reported

Behaviour: clinically important change in general behaviour · people with primary delusional infestation

1 finding from 1 review

Treatments for primary delusional infestation 2019 · Cochrane Headline outcomes only
no estimate extracted
0 participants
GRADE not reported

Haloperidol discontinuation vs haloperidol continuation

Behaviour: clinically important change in general behaviour · schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol discontinuation for people with schizophrenia 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Parenting interventions vs controls

Behaviour of child: clinically important change in specific aspects of behaviour · parents with schizophrenia or related serious mental illness

1 finding from 1 review

Parenting interventions for people with schizophrenia or related serious mental illness 2021 · Cochrane Headline outcomes only
no estimate extracted
0 participants
GRADE not reported

α‐FLUPENTHIXOL vs PLACEBO or β‐FLUPENTHIXOL

Mental state and behaviour: clinically important change in general mental state and behaviour · patients with schizophrenia

1 finding from 1 review

Flupenthixol versus placebo for schizophrenia 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
GRADE not reported

ARIPIPRAZOLE (IM) vs OLANZAPINE

Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)

ARIPIPRAZOLE (IM) may leads to lower specific behaviour: Agitation ‐ clinically important change (PANSS… compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (low certainty).

1 finding from 1 review

Aripiprazole (intramuscular) for psychosis‐induced aggression or agitation (rapid tranquillisation) 2018 · Cochrane Headline outcomes only
RR 0.77 [0.6, 0.99]
1 study · 80 participants
Low

ARIPIPRAZOLE (IM) vs PLACEBO/NIL

Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)

It is very uncertain whether ARIPIPRAZOLE (IM) changes specific behaviour: Agitation ‐ clinically important change (PANSS… compared with PLACEBO/NIL (very low certainty).

1 finding from 1 review

Aripiprazole (intramuscular) for psychosis‐induced aggression or agitation (rapid tranquillisation) 2018 · Cochrane Headline outcomes only
RR 1.5 [1.17, 1.92]
2 studies · 382 participants
Very low

ARIPIPRAZOLE (IM) vs haloperidol

Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)

It is very uncertain whether ARIPIPRAZOLE (IM) changes specific behaviour: Agitation ‐ clinically important change (PANSS… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).

1 finding from 1 review

Aripiprazole (intramuscular) for psychosis‐induced aggression or agitation (rapid tranquillisation) 2018 · Cochrane Headline outcomes only
RR 0.94 [0.8, 1.11]
2 studies · 477 participants
Very low